10397-28-1

Usage

InChI:InChI=1/C8H6ClNO4/c1-14-7-3-2-5(8(9)11)4-6(7)10(12)13/h2-4H,1H3

Upstream product

• 89-41-8 4-methoxy-3-nitrobenzoic acid 
• 100-09-4 4-methoxybenzoic acid 

Downstream Products

• 349137-21-9 4-methoxy-3-nitro-benzoic acid-(2-bromo-ethylamide) 
• 861301-65-7 [4-(4-methoxy-3-nitro-benzoylamino)-phenyl]-arsonic acid 
• 861789-48-2 {4-[4-methoxy-3-(4-methoxy-3-nitro-benzoylamino)-benzoylamino]-phenyl}-arsonic acid 
• 860594-57-6 4,4'-dimethoxy-3-nitro-benzophenone 
• 98997-38-7 4-methoxy-3-aminobenzoylurea 
• 333350-60-0 4-methoxy-3-nitro-benzoic acid methylamide 
• 69819-07-4 4-methoxy-3-nitro-N-(5-nitro-thiazol-2-yl)-benzamide 
• 22978-17-2 N-Cyanomethyl-4-methoxy-3-nitro-benzamide 
• 82571-94-6 4-methoxy-3-nitro-benzophenone 
• 206649-15-2 4-methoxy-3-nitro-N-(3,4,5-trimethoxyphenyl)benzamide 
• 206649-17-4 4-Methoxy-3-nitro-N-(3,4,5-trimethoxy-phenyl)-thiobenzamide 

Relevant academic research and scientific papers

Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor

In this study, a series of novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety was described for ALK inhibitor. The pyrazole, imidazole, 1,2,4-triazole, piperazine and phenanthridine moieties were employed at the 2-position of pyrimidine. Amo

Design, synthesis, and biological evaluation of 4-methoxy-3-arylamido-N-(substitutedphenyl)benzamide derivatives as potential antiplatelet agents

A series of 4-methoxy-3-arylamido-N-(substitutedphenyl)benzamides 6a–u were designed according to the splicing principle of structural design in the medicinal chemistry theory and were synthesized in five steps: nitration, acylation, ammoniation, reduction, and secondary ammoniation. The structures of the target compounds were characterized and verified by infrared, 1H nuclear magnetic resonance (NMR), 13C NMR, and electron spray ionization spectroscopy. Their in vitro antiplatelet aggregation activities induced by adenosine diphosphate (ADP) or arachidonic acid (AA) were assessed by Born's method. The biological evaluation revealed that all compounds exhibited certain levels of activities in both of the antiplatelet aggregation assays; compounds 6c (IC50 = 3.84 μM) and 6f (IC50 = 3.12 μM) displayed the strongest antiplatelet aggregation activities in the ADP-induced and AA-induced assay, separately. Moreover, compounds that had stronger activities were chosen for cell toxicity testing via the cell counting kit-8 assay. The results indicated that none of the compounds had obvious cell toxicity against L929 cells at the doses of 10 and 20 μM. It is worth pointing out that compound 6c showed the highest antiplatelet activity and the lowest cell toxicity. In general, 4-methoxy-3-arylamido-N-(substitutedphenyl)benzamides have the potential to become a kind of safer and more effective antiplatelet agents.

Tubulin inhibitors: Discovery of a new scaffold targeting extra-binding residues within the colchicine site through anchoring substituents properly adapted to their pocket by a semi-flexible linker

Bis-hydrazides 13a-h were designed and synthesized as potential tubulin inhibitors selectively targeting the colchicine site between α- and β-tubulin subunits. The newly designed ring-B substituents were assisted at their ends by ‘anchor groups’ which are expected to exert binding interaction(s) with new additional amino acid residues in the colchicine site (beyond those amino acids previously reported to interact with reference inhibitors as CA-4 and colchicine). Conformational flexibility of bis-hydrazide linker assisted these ‘extra-binding’ properties through reliving ligands’ strains in the final ligand-receptor complexes. Compound 13f displayed the most promising computational and biological study results in the series: MM/GBSA binding energy of ?62.362 kcal/mol (extra-binding to Arg α:221, Thr β:353 & Lys β:254); 34% NCI-H522 cells’ death (at 10 μM), IC50 = 0.073 μM (MTT assay); significant cell cycle arrest at G2/M phase; 11.6% preG1 apoptosis induction and 83.1% in vitro tubulin inhibition (at concentration = IC50). Future researchers in bis-hydrazide tubulin inhibitors are advised to consider the 2-chloro-N-(4-substituted-phenyl)acetamide derivatives as compound 13f due to extra-binding properties of their ring B.

Synthesis process of anti-tumor drug Sapanisertib

The invention discloses a synthesis process of anti-tumor drug Sapanisertib. The synthesis process comprises the following steps: step 1, carrying out carboxyl halogenation reaction on a compound I and a halogenating reagent in a proper solvent to obtain

Straightforward α-Amino Nitrile Synthesis Through Mo(CO)6-Catalyzed Reductive Functionalization of Carboxamides

The selective reduction of amides into an intermediate hemiaminal catalyzed by Mo(CO)6 together with the inexpensive and easy to handle TMDS (1,1,3,3-tetramethyldisiloxane) as reducing agent, followed by subsequent trapping of the hemiaminal with a cyanide source, allows for the straightforward synthesis of α-amino nitriles. The methodology presented here, displays high levels of chemoselectivity allowing for the reduction of amides in the presence of functional groups such as ketones, imines, aldehydes, and acids, which affords a simple route for the synthesis of α-amino nitriles with a broad scope of functionalities in high yields. Furthermore, the applicability of this methodology is demonstrated by scale up experiments and by derivatization of the target compounds into synthetically interesting products. The selective cyanation is successfully applied in late stage functionalizations of amide containing drugs and prolinol derivatives.

3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G

Disclosed are novel benzamide compounds and the uses thereof for treating diseases and disorders in a patient in need thereof by increasing cellular levels of A3G and/or other members of the A3 family of proteins in the patient. The disclosed compounds in

PIGMENT DISPERSANT, AND PIGMENT COMPOSITION, COLORING COMPOSITION AND COLOR FILTER USING THE SAME

PROBLEM TO BE SOLVED: To provide a pigment dispersant that exhibits an extremely good characteristic in enhancing the dispersibility of pigment, to provide a pigment composition, produced by using the pigment dispersant, that is excellent in the contrast

The pigment composition, a colored composition, color filter

PROBLEM TO BE SOLVED: To provide a pigment composition that is excellent, when used for a color filter, in its contrast ratio and luminance, has a good heat resistance and light stability, and does not generate a coated film foreign body, as well as to pr

A practical in situ generation of the schwartz reagent. reduction of tertiary amides to aldehydes and hydrozirconation

A new, highly efficient in situ protocol (Cp2ZrCl2/LiAlH(OBu-t)3) is described for the generation of the Schwartz reagent which provides a convenient method for the amide to aldehyde reduction and the regioselective hydrozirconation-iodination of alkynes and alkenes. Highlighted are chemoselective reductions of benzamides derived by directed ortho metalation (DoM) chemistry, allowing the synthesis of valuable 1,2,3-substituted benzaldehydes. The single-step, three-component process proceeds in a very short reaction time, shows excellent functional group compatibility, and uses inexpensive and long-storage stable reducing reagents.

NOVEL COMPOUNDS

The present invention relates substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.